Violation Tracker Individual Record
Date:October 26, 2006
Offense Group:healthcare-related offenses
Primary Offense:off-label or unapproved promotion of medical products
InterMune, Inc, a Brisbane, Cal., biopharmaceutical company, agreed to pay the United States more than $36.9 million to resolve criminal charges and civil liabilities in connection with its alleged illegal promotion and marketing of Actimmune.
Level of Government:federal
Action Type:agency action
Agency:Justice Department Civil Division
Civil or Criminal Case:civil and criminal
Prosecution Agreement:deferred prosecution agreement
HQ Country of Parent:Switzerland
Ownership Structure of Parent:publicly traded
Major Industry of Parent:pharmaceuticals
Specific Industry of Parent:pharmaceuticals
Source Notes:If an online information source is not working, check the Violation Tracker Data Sources page for an updated link.